/PRNewswire/ Oblique Therapeutics AB (publ.), a biotechnology company focused on new antibody medicines for severe diseases with large unmet medical needs,.
GOTHENBURG, Sweden, Nov. 9, 2022 /PRNewswire/ Oblique Therapeutics AB (publ.), a biotechnology company focused on new antibody medicines for severe diseases with large unmet medical needs
Gothenburg, Sweden,9 November 2022 – Oblique Therapeutics AB (publ.), a biotechnology company focused on new antibody medicines for severe diseases with large unmet medical needs, is pleased to announce the confirmation of Christer Nordstedt MD.PhD. as Chief Executive Officer (CEO). Christer Nordstedt will assume the position on 1st December 2022.